The effect of cannabidiol (300 mg) on fear conditioning.

Gepubliceerd: 04-12-2017 Laatst bijgewerkt: 18-08-2022

Ethische beoordeling	Niet van toepassing
Status	Werving nog niet gestart
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON28474

Bron
NTR

Aandoening

Anxiety, fear conditioning
Angst, angstconditionering

Ondersteuning

Primaire sponsor: Utrecht University
Overige ondersteuning: NWO/ZonMw

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

Both subjective and objective parameters pertaining to fear conditioning and fear extinction will be assessed, the main physiological measure is the fear potentiated startle reflex.

Toelichting onderzoek

Onderzoeksopzet

fear acquisition, fear expression, fear extinction, fear retention, reinstatement

Onderzoeksproduct en/of interventie

Capsule with 300 mg cannabidiol of placebo

Contactpersonen

Publiek

Febe Flier, van der
Utrecht
The Netherlands

Wetenschappelijk

Febe Flier, van der
Utrecht
The Netherlands

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

- Male or female volunteers between 18 and 30 years.

- Judged to be in good physical and mental health on the basis of the medical history according to self-report.

- Have a normal binocular acuity, corrected or uncorrected.

- Female participants must declare they are on reliable birth control.

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

- History of any disease, e.g. neurological disorders, psychiatric disorders, which in the opinion of the investigator may confound the results of the study.

- Present any other conditions in that in the investigators', the subjects' personal or the study physicians' opinion may confound the results of the study.

- History of psychotic disorder/psychosis and/or having a first/second degree family member with (a history of) psychotic disorder/psychosis.

- Current diagnosis of an Axis I or Axis II psychiatric disorder, or suffering from an Axis I or Axis II psychiatric disorder within 4 weeks prior to the study.

- Current cardiac disease and/or history of cardiac disease.

- Known hypersensitivity to CBD.

- History of cannabinoids exopsure with adverse reactions.

- History of severe allergy or general drug hypersensitivity.

- History of abuse or current regular use of cannabis more than once a week.

- Usage of psychoactive drugs in the four weeks prior to the study.

- Current use of drugs of abuse or indications (urine screening)

- History of epilepsy.

- Pregnancy, i.e., a positive β-HCG urine test.

- Lactating.

- Reduced startle reactivity, defined as no discernable response in at least 3 out of the 12 startle stimuli presented at screening.

Onderzoeksopzet

Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Factorieel
Toewijzing:	Gerandomiseerd
Blindering:	Dubbelblind
Controle:	Placebo

Deelname

Nederland

Status:	Werving nog niet gestart
(Verwachte) startdatum:	01-01-2018
Aantal proefpersonen:	56
Type:	Verwachte startdatum

Ethische beoordeling

Niet van toepassing

Soort:	Niet van toepassing

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL6714
NTR-old	NTR6893

Register	ID
Ander register	: METC NL63520.041.17

Resultaten